T1	Participants 61 129	metastatic or recurrent squamous cell carcinoma of the head and neck
T2	Participants 381 529	recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy
T3	Participants 611 635	43 centers; 124 patients
T4	Participants 967 1003	A total of 121 patients were treated
T5	Participants 1907 1916	R/M HNSCC
